Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPU-118 tablets in advanced malignant solid tumors
CTR20221352Phase 2Completed
- Sponsor
- China Pharmaceutical University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oroxylin A in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), sponsored by China Pharmaceutical University. Started Aug 2022; status: completed.
02
Drugs
oroxylin A
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221352.